Emerging Markets Report - NeuroOne Medical Technologies Receives FDA 510(k) Clearance

ORLANDO, Fla., Jan. 21, 2020 (GLOBE NEWSWIRE) -- For investors seeking outsized growth, Life Sciences--the more speculative end of the healthcare sector--is certainly one sub-industry that’s hard to beat. Granted, investments in this space might carry a greater degree of risk, but that can be said of almost any prospect in an emerging high-growth industry. When it comes to Life Sciences, the demand for innovation is arguably a key factor. The capacity to disrupt standard industry practice is a critical element that investors focus on to determine a company’s potential for success or likelihood of failure.

But no matter how innovative a company in this space may be, or no matter how well-managed its operations, regulatory clearance is the gatekeeper to a product’s commercial entrance or endpoint. So, when a company receives FDA clearance--the green light that allows a company to commercialize its product--it’s a big deal.

Among the latest emerging healthcare companies to gain FDA clearance is NeuroOne Medical Technologies Corporation (OTC: NMTC), a medical device company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson's Disease, Essential Tremors and other related neurological disorders such as back pain that may improve patient outcomes and reduce procedural costs.

Turning Brain Signals Into Actionable Solutions
NeuroOne specializes in developing electrodes to record, stimulate, or ablate sections of the brain. Designed as a minimally invasive solution, NeuroOne’s devices are focused on treating and diagnosing patients who suffer from neurological conditions such as epilepsy, essential tremors, Parkinson’s disease, dystonia, pain from failed back surgeries and potentially any pain caused by nerve damage.

For investors who are unfamiliar with this medical practice, neurostimulation works by altering brain signals. It modulates activity in the nervous system. A specialized discipline in the medical industry, neurostimulation exists in many forms, from cochlear implants to deep brain stimulation.

As a therapy for patients suffering from Parkinson’s disease, epilepsy, and dystonia (among others), the use of neurostimulation is still a relatively new field. The problem is there has been zero innovation in electrode therapy in the marketplace for many years. All the focus has been on the impulse generator and software creating a gap for the device that is actually in contact with the problematic area of the body. NeuroOne's technology is scalable meaning the technology is capable of increasing the number of contacts on a footprint that today has fewer (but larger) contacts. In essence, an electrode today that has 16 contacts could be increased in multiples by making the contacts smaller. This allows the surgeon more precision in what he stimulates, records or ablates.